Avience Biomedicals IPO Subscribed 385.05 Times on Day 3

Avience Biomedicals Limited's initial public offering (IPO) closed its three-day subscription window with exceptional investor interest, reaching 385.05 times overall subscription by 4:55 PM on Day 3 (June 22, 2026). The ₹30.24 crore book-build issue, priced at ₹196 to ₹208 per share, received bids for 37,03,44,000 shares against 9,61,800 shares on offer, with total applications reaching 1,92,742.

Invest in Indian Markets and Unlock Future Potential With 5paisa!

Open Account Now

Subscription Status of Avience Biomedicals IPO

Here are the subscription details for Avience Biomedicals IPO Day 3, as of 5:04 PM:

Key Highlights – Day 3

• Overall subscription surged to 385.05 times on the final day, from Day 2's 43.79 times, driven by a sharp last-day surge in institutional demand.
• Non-institutional investors led with exceptional demand at 597.21 times, surging from Day 2's 66.36 times, with bNII at 670.18 times and sNII at 451.27 times, reflecting extraordinary HNI appetite for this molecular diagnostics SME IPO.
• Individual investors recorded strong participation at 400.84 times, surging from Day 2's 58.97 times.
• Qualified institutional buyers (ex-anchor) surged to 196.77 times from Day 2's negligible 0.03 times, indicating massive institutional interest concentrated on the closing day.

Key Highlights – Day 2

• Overall subscription reached 43.79 times, surging from Day 1's 10.75 times.
• Non-institutional investors improved to 66.36 times from Day 1's 13.49 times, with bNII at 66.08 times and sNII at 66.91 times.
• Individual investors improved to 58.97 times from Day 1's 15.69 times.
• Qualified institutional buyers (ex-anchor) showed negligible participation at 0.03 times, with no meaningful entry on Day 2.
   

Key Highlights – Day 1

• Overall subscription crossed full subscription at 10.75 times on Day 1 (June 18, 2026), reflecting strong initial investor interest in this molecular diagnostics SME IPO.
• Individual investors led opening participation at 15.69 times on Day 1.
• Non-institutional investors recorded strong demand at 13.49 times, with bNII at 13.66 times and sNII at 13.14 times on Day 1.
• Qualified institutional buyers (ex-anchor) showed no participation on Day 1.
• Anchor investors fully subscribed their allocation of ₹8.52 crores on June 17, 2026.

About Avience Biomedicals Limited

Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specialising in manufacturing, supplying, and exporting molecular diagnostic solutions including rapid test kits, biochemistry analysers, hematology analysers, molecular diagnostic kits, and medical devices. The company serves pathology labs, microbiology labs, hospitals, and research centres in India and overseas, operating on a B2B and B2G model from its manufacturing unit in Noida, Uttar Pradesh.